Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Gene profiling and circulating tumor cells as biomarker to prognostic of patients with locoregional breast cancer.
Kuniyoshi RK
,
Gehrke Fde S
,
Alves BC
,
Vilas-Bôas V
,
Coló AE
,
Sousa N
,
Nunes J
,
Fonseca FL
,
Del Giglio A
.
???displayArticle.abstract???
The gene profile of primary tumors, as well as the identification of circulating tumor cells (CTCs), can provide important prognostic and predictive information. In this study, our objective was to perform tumor gene profiling (TGP) in combination with CTC characterization in women with nonmetastatic breast cancer. Biological samples (from peripheral blood and tumors) from 167 patients diagnosed with stage I, II, and III mammary carcinoma, who were also referred for adjuvant/neoadjuvant chemotherapy, were assessed for the following parameters: (a) the presence of CTCs identified by the expression of CK-19 and c-erbB-2 in the peripheral blood mononuclear cell (PBMC) fraction by quantitative reverse transcription PCR (RT-PCR) and (b) the TGP, which was determined by analyzing the expression of 21 genes in paraffin-embedded tissue samples by quantitative multiplex RT-PCR with the Plexor® system. We observed a statistically significant correlation between the progression-free interval (PFI) and the clinical stage (p = 0.000701), the TGP score (p = 0.006538), and the presence of hormone receptors in the tumor (p = 0.0432). We observed no correlation between the PFI and the presence or absence of CK-19 or HER2 expression in the PBMC fraction prior to the start of treatment or in the two following readouts. Multivariate analysis revealed that only the TGP score significantly correlated with the PFI (p = 0.029247). The TGP is an important prognostic variable for patients with locoregional breast cancer. The presence of CTCs adds no prognostic value to the information already provided by the TGP.
Apostolaki,
Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance.
2007, Pubmed
Apostolaki,
Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance.
2007,
Pubmed
Camara,
The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer.
2007,
Pubmed
Cristofanilli,
Circulating tumor cells, disease progression, and survival in metastatic breast cancer.
2004,
Pubmed
Daskalaki,
Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer.
2009,
Pubmed
Filipits,
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
2011,
Pubmed
Fisher,
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
2004,
Pubmed
Fonseca,
Peripheral blood c-erbB-2 expression by reverse transcriptase-polymerase chain reaction in breast cancer patients receiving chemotherapy.
2002,
Pubmed
Gianni,
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
2005,
Pubmed
Ignatiadis,
Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer.
2007,
Pubmed
Lobodasch,
Quantification of circulating tumour cells for the monitoring of adjuvant therapy in breast cancer: an increase in cell number at completion of therapy is a predictor of early relapse.
2007,
Pubmed
Manhani,
CK-19 expression by RT-PCR in the peripheral blood of breast cancer patients correlates with response to chemotherapy.
2001,
Pubmed
Mikulová,
Methods for detection of circulating tumour cells and their clinical value in cancer patients.
2011,
Pubmed
Novaes,
Reverse transcriptase-polymerase chain reaction analysis of cytokeratin 19 expression in the peripheral blood mononuclear cells of normal female blood donors.
1997,
Pubmed
Pachmann,
Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse.
2008,
Pubmed
Paik,
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
2004,
Pubmed
Pusztai,
Current status of prognostic profiling in breast cancer.
2008,
Pubmed
Ring,
Circulating tumour cells in breast cancer.
2004,
Pubmed
Savino,
Development of real-time quantitative reverse transcription-PCR for Her2 detection in peripheral blood from patients with breast cancer.
2007,
Pubmed
Strati,
Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR.
2011,
Pubmed
Toussaint,
Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues.
2009,
Pubmed
Wang,
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
2005,
Pubmed
You,
Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells.
2008,
Pubmed
van de Vijver,
A gene-expression signature as a predictor of survival in breast cancer.
2002,
Pubmed
Čabiňaková,
Disseminated and circulating tumour cells and their role in breast cancer.
2012,
Pubmed
